HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Diode laser ablation for threshold retinopathy of prematurity: short-term structural outcome.

AbstractOBJECTIVE:
To describe short-term structural outcomes and associated ocular complications in premature infants treated with diode laser ablation for retinopathy of prematurity.
METHODS:
The records of all infants who were diagnosed as having threshold retinopathy of prematurity and treated with diode laser therapy at our hospital from January 1, 1992, through December 31, 1996, were retrospectively reviewed. Sixty-four eyes reached threshold during this period. Three eyes received cryotherapy in addition to laser treatment and were excluded, leaving 61 eyes eligible for review.
RESULTS:
Of the 61 eyes with threshold disease treated exclusively with diode laser, 4 (7%) had zone I disease and 57 (93%) had zone II disease at the time of initial laser treatment. Three (5%) of the 61 eyes progressed to stage 4 disease (2 eyes, stage 4A; 1 eye, stage 4B). There were no cataracts or other ocular complications noted secondary to laser treatment based on short-term follow-up (mean follow-up, 120 days).
CONCLUSION:
In this population of infants, diode laser ablation appears to be a safe and effective treatment for threshold retinopathy of prematurity.
AuthorsM H DeJonge, P J Ferrone, M T Trese
JournalArchives of ophthalmology (Chicago, Ill. : 1960) (Arch Ophthalmol) Vol. 118 Issue 3 Pg. 365-7 (Mar 2000) ISSN: 0003-9950 [Print] United States
PMID10721959 (Publication Type: Journal Article)
Topics
  • Birth Weight
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Laser Therapy
  • Retina (surgery)
  • Retinal Detachment (surgery)
  • Retinopathy of Prematurity (classification, surgery)
  • Retrospective Studies
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: